On the evening of April 17, HYGEIA HEALTH (06078) announced a buyback of 248,000 shares. This marks the company's fifth share repurchase since the beginning of April. After hitting an interim high of HKD 14.55 during intraday trading on February 23, the company's stock price experienced a significant correction. Between February 23 and March 26, the share price accumulated a decline of 23.17%, with the price falling as low as HKD 11.00 during this period.

On March 30, HYGEIA HEALTH disclosed its 2025 financial report. The report indicated that the company maintained stable performance and robust cash flow under the healthcare insurance DRG/DIP policy, delivering commendable results. The company resumed its share buyback program on March 31, which subsequently stimulated a 6.84% surge in the stock price on April 1, accompanied by increased trading volume. This served as a key signal for a recent rebound in the company's share price.

To further boost market confidence, HYGEIA HEALTH executed a substantial buyback of 435,200 shares on March 31, costing nearly HKD 5 million, and conducted another repurchase on April 2. Although the April 2 buyback was limited to only 2,200 shares due to Hong Kong stock exchange rules concerning the maximum repurchase price, the company proceeded with four additional buybacks over the following two weeks, repurchasing 243,600, 247,400, 241,000, and 248,000 shares respectively. Each of these repurchases involved approximately HKD 3 million.

However, the frequent buybacks did not provide further impetus for HYGEIA's stock price to advance. From April 2 to April 17, the company's share price even declined by 2.35%, largely moving sideways on the chart. This suggests that the stock's short-term trend has reached a critical juncture.

**A 20%+ Price Drop: Approaching the Eve of a "Defensive Battle"?** As mentioned, HYGEIA HEALTH's share price fell 23.17% between February 23 and March 26. This decline was primarily driven by a confluence of factors. Since the start of the year, HYGEIA HEALTH has conducted a total of nine buybacks, with the initial repurchases concentrated in February. Notably, the company repurchased 358,800 shares on February 25, but the stock price closed down 4.87% the following day. The onset of the pre-earnings blackout period, during which companies are prohibited from repurchasing shares, was undoubtedly a key turning point that led to the reversal from gains to losses.

The "buyback blackout period" stems from a rule established by the Hong Kong Exchange in 2009 to prevent insider trading. This rule explicitly prohibits listed companies from repurchasing their own shares or engaging in any transactions that could influence the stock price during the month preceding the announcement of their financial results. Therefore, after its final pre-blackout buyback on February 25, HYGEIA was forced to suspend repurchases throughout March due to the blackout period. This resulted in the loss of daily buying support of roughly HKD 5 million. Compounding this, the overall liquidity contraction in the Hong Kong stock market at the time, coupled with a 5.7% drop in the Hang Seng Index and continued foreign capital outflows, exerted systemic pressure on small-cap stocks like HYGEIA HEALTH, which has a market capitalization below HKD 10 billion, thereby amplifying the decline in its share price.

Simultaneously, the "uncertainty" surrounding the impending implementation of the updated version 3.0 of the healthcare insurance DRG/DIP grouping scheme was another significant factor affecting HYGEIA's stock price. While some investors believed the new rules could benefit specialized oncology groupings (such as an expanded scope for special case negotiations), many seemed more concerned that ongoing medical insurance cost controls would continue to suppress the profit margins of private hospitals. This debate over policy uncertainty translated into shifting market sentiment, concretely manifesting as a 14.08% drop in HYGEIA's share price during March.

Subsequently, the company's stock price gradually stabilized after the official release of the DRG/DIP 3.0 grouping scheme on March 20, which alleviated much of the panic stemming from uncertainty. However, this panic-driven sell-off caused HYGEIA's stock price to fall over 20% within a single month, with its market capitalization dipping to HKD 6.765 billion at the lowest point, undoubtedly serving as a warning sign. Based on data analysis, the current market's potential "delisting warning threshold" is considered to be around HKD 6.764 billion. Following the previous significant decline, HYGEIA HEALTH's average market capitalization during the review period has fallen to HKD 8.275 billion. This implies that if the stock price declines further, it could potentially trigger a "battle to maintain listing status."

**Why Have Solid Performance + Share Buybacks Become "Ineffective"?** From a short-term perspective, although the resumption of buybacks on March 31 provided some stimulus for HYGEIA's stock price the next day, the subsequent repurchases in April failed to propel the rebound further. Has the combination of solid performance and share buybacks lost its effectiveness?

The financial report shows that for the reporting period, HYGEIA HEALTH achieved revenue of RMB 4.01 billion in 2025, a year-on-year decrease of 9.8%. Concurrently, due to a recognized RMB 280 million asset impairment related to goodwill from the Etern Group, the company's net profit was RMB 160 million, a sharp year-on-year decline of 73.0%. The adjusted net profit, which excludes this one-off item, was RMB 460 million, down 24.4% year-on-year.

Regarding profitability, the company's gross profit margin for the period was 25.5%, down 4.4 percentage points year-on-year. This was mainly attributable to newly built hospitals being transferred to fixed assets and the ramp-up of bed utilization rates in 2025, combined with pressure on revenue per customer due to medical insurance cost controls, leading to a noticeable decline in the gross margin. Nevertheless, HYGEIA managed to narrow the decline in its adjusted net profit margin attributable to owners through cost control measures. Data indicates its adjusted net profit margin attributable to owners was 18.4% for the period, down 1.3 percentage points year-on-year.

Operationally, revenue from outpatient services and inpatient services amounted to RMB 1.48 billion and RMB 2.42 billion respectively, declining by 9.4% and 10.2% year-on-year. However, the total number of patient visits for the full year reached 4.6 million, a slight increase of 1.5% compared to the previous year, indicating stable patient volumes across HYGEIA's hospitals.

Data from the second half of 2025 (25H2) shows a more pronounced recovery trend. On a half-yearly basis, the company generated revenue of RMB 2.02 billion in 25H2, a sequential increase of 1.5%. In terms of patient visits, the number reached 2.4 million for the period, a sequential increase of 9.1%. The significance of this data lies in its indication that demand for HYGEIA's hospital services remains unaffected. The actual impact of the DRG payment reform appears to be primarily a reduction in revenue per unit across its hospitals. For a company focused on expanding its network in lower-tier cities, cost control, and supply chain integration, this is not considered a critical weakness.

Furthermore, the report explicitly mentioned efforts to optimize capital allocation. In 2025, the company generated net operating cash flow of RMB 950 million (a historical high). Capital expenditures were RMB 480 million, down 21.4% year-on-year. Free cash flow reached RMB 470 million, surging 407.0% year-on-year, indicating a significant improvement in cash generation. Additionally, as of the end of 2025, the company's outstanding interest-bearing debt stood at RMB 2.44 billion, down 12.3% year-on-year, further reducing financial costs associated with debt and potentially alleviating some downward pressure on future profits.

Despite the combination of stable operational metrics and share buybacks, the recent short-term performance of HYGEIA's stock price has clearly fallen short of expectations. Analysis of the current chip distribution chart suggests the average cost basis for outstanding shares is around HKD 12.72. The current stock price is below this average cost. The proportion of shares held at a profit is only 27.88%. This indicates that following the previous month's decline, a significant volume of shares are held at a loss. A potential double-peak pattern is forming around the average cost line, with the high-cost peak not yet sufficiently depleted, creating persistent overhead resistance that suppresses upward price movement.

Although the timely resumption of buybacks on March 31 provided a boost, the positive impact of subsequent continued repurchases has been difficult to manifest in the short-term price action due to technical chart pressure. The stock appears to have a clear need for a period of consolidation or even a pullback. Under these circumstances, HYGEIA HEALTH's stock price may face a consolidation phase. A sustained rebound is likely only after the selling pressure from higher price levels gradually diminishes.